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We have used adenovirus-mediated gene transfer in
mice to investigate low density lipoprotein receptor
(LDLR) and LDLR-related protein (LRP)-independent
mechanisms that control the metabolism of chylomicron
and very low density lipoprotein (VLDL) remnants in
vivo. Overexpression of receptor-associated protein
(RAP) in mice that lack both LRP and LDLR
(MX1cre1LRPflox/floxLDLR2/2) in their livers elicited a
marked hypertriglyceridemia in addition to the pre-ex-
isting hypercholesterolemia in these animals, resulting
in a shift in the distribution of plasma lipids from LDL-
sized lipoproteins to large VLDL-sized particles. This
dramatic increase in plasma lipids was not due to a
RAP-mediated inhibition of a unknown hepatic high af-
finity binding site involved in lipoprotein metabolism,
because no RAP binding could be detected in livers of
MX1cre1LRPflox/floxLDLR2/2 mice using both membrane
binding studies and ligand blotting experiments. Re-
markably, RAP overexpression also resulted in a 7-fold
increase (from 13.6 to 95.6 ng/ml) of circulating, but
largely inactive, lipoprotein lipase (LPL). In contrast,
plasma hepatic lipase levels and activity were unaf-
fected. In vitro studies showed that RAP binds to LPL
with high affinity (Kd 5 5 nM) but does not affect its
catalytic activity, in vitro or in vivo. Our findings sug-
gest that an extrahepatic RAP-sensitive process that is
independent of the LDLR or LRP is involved in metab-
olism of triglyceride-rich lipoproteins. There, RAP may
affect the functional maturation of LPL, thus causing
the accumulation of triglyceride-rich lipoproteins in the
circulation.
Hypertriglyceridemia, combined with the accumulation of
remnant lipoproteins in the circulation, is a major risk factor
for atherosclerosis and coronary artery disease. The genetic
bases of this clinically important syndrome are complex and
incompletely understood. Two endocytotic receptor systems are
known to remove the lipolyzed remnants of chylomicrons and
very low density lipoproteins (VLDL)1 from the circulation.
They are the low density lipoprotein (LDL) receptor and the
LDL receptor-related protein (LRP) (1, 2). Following lipolysis in
the peripheral capillaries of muscle, heart, and adipose tissue,
where chylomicrons deliver most of the triglyceride load they
carry, the remnants have shrunk to a size at which they can
permeate the fenestrated endothelium separating the hepato-
cyte surface and the space of Disse from the circulation (for
review see Ref. 3). LRP and LDL receptors at the surface of
hepatocytes bind and clear remnant lipoproteins from an in-
termediate binding site. This intermediate compartment is cre-
ated by interactions of heparan sulfate proteoglycans (4), he-
patic lipase (5, 6), lipoprotein lipase (7), and apoE (8) with the
remnants.
Gene knockout and gene transfer experiments in mice have
defined the roles of the receptors, apoproteins, and lipases in
the remnant clearance process. Although the LDL receptor
efficiently removes apoB100-containing LDL, as well as
apoB48- containing remnants through interaction with apoE
(9, 10), from the bloodstream, LRP binds B48-containing rem-
nants exclusively through apoE (11–13).
The LRP receptor-associated protein (RAP), a specialized
chaperone that is required for biosynthesis of LRP, blocks the
binding function of this receptor in vitro and in vivo and has
been successfully used to transiently inactivate LRP in adult
mice (14). These experiments have revealed a physiological role
of the LDL receptor and LRP in remnant removal. In the
absence of functional LDL receptor in knockout mice, inhibition
of LRP by adenovirus-mediated gene transfer and overexpres-
sion of RAP resulted in the accumulation of large, triglyceride-
and cholesterol-rich apoB48-containing remnants.
In another gene knockout model generated in mice, LRP has
recently been inactivated by inducible tissue-specific tech-
niques using the Cre-lox recombination system (2). By this
approach, it was possible to circumvent the early embryonic
lethal phenotype caused by conventional gene disruption of
LRP (15, 16). LRP inactivation was initiated in adult mice
following interferon induction, which in turn led to expression
of the cre recombinase from the interferon inducible MX1 pro-
moter (17). Recombination of the loxP flanked (floxed) LRP
gene was essentially complete in hepatocytes and other cell
types exposed to the circulating interferons.
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As in the RAP overexpression experiments (14), LRP gene
disruption in LDL receptor-deficient mice did cause the accu-
mulation of cholesterol-rich, apoB48-containing remnants.
However, these remnants were smaller and contained signifi-
cantly less triglyceride than those that accumulated in the RAP
overexpressing animals. These observations suggest that a
novel and hitherto unsuspected RAP-sensitive process is in-
volved in the metabolism of triglyceride-rich lipoproteins. This
could involve other RAP-sensitive receptors, such as the hypo-
thetical lipolysis stimulated receptor (18), or a direct or indirect
effect of RAP on lipase-mediated conversion of chylomicrons to
the smaller remnants.
In this study we have addressed this question by measuring
the effect of RAP overexpression on remnant removal in ani-
mals in which the LDL receptor, LRP, or both proteins had
been inactivated. We have also investigated the presence of
other potential RAP-binding sites in LRP and LDL receptor-
deficient mouse liver membranes. Furthermore, we have deter-
mined the protein mass and catalytic activity of hepatic lipase
and lipoprotein lipase in RAP overexpressing mice. Our results
suggest that RAP affects the conversion of large triglyceride-
rich chylomicrons to smaller remnants by interfering with LPL
activation in the periphery and rule out the contribution of
other major RAP-binding proteins in the liver. The biochemical
basis underlying this process may play a role in some of the
complex genetic traits that cause hypertriglyceridemia in man.
EXPERIMENTAL PROCEDURES
Transgenic Animals—Mice in which the LRP alleles have been al-
tered by introduction of loxP sites (LRPflox/flox) were generated by ho-
mologous recombination of the LRP allele in embryonic stem cells and
have been described previously (19). Mice transgenic for the MX1cre
expression construct were generated by pronuclear injection of hybrid
(SJLxC57BL/6J) mice (2). LDL receptor-deficient (LDLR2/2) mice were
generated by homologous recombination of the LDLR allele in embry-
onic stem cells and have been described previously (10). Six genetically
distinct strains of animals were used: mice that were wild type at both
LRP loci, deficient for the LDL receptor (LDLR2/2), homozygous for the
floxed LRP allele (LRPflox/flox), homozygous for both mutations (LRPflox/
floxLDLR2/2), homozygous for the floxed LRP and transgenic for the
MX1cre transgene (MX1cre1LRPflox/flox), and homozygous for the floxed
LRP allele, deficient for the LDL receptor, and transgenic for the
MX1cre transgene (MX1cre1LRPflox/floxLDLR2/2). Induction with polyi-
nosinic:polycytidylic ribonucleic acid (pI:pC; Sigma) was done by intra-
peritoneal injection of 250 mg of a 1 mg/ml solution of pI:pC in water.
Injections were repeated three times at 2-day intervals. For experi-
ments, mice 10–16 weeks of age were included. Mice were housed under
standard conditions in conventional cages and given free access to food
(i.e. regular rodent chow containing 6% fat (Teklad Premier laboratory
Diets, Madison, WI) and water.
Adenovirus Transfections—Recombinant adenoviruses containing
the rat RAP cDNA (Ad-RAP) and b-galactosidase cDNA (Ad-b-Gal)
driven by the cytomegalovirus promoter were generated, grown, and
purified as described previously (14). For in vivo adenovirus transfec-
tion, four weeks after the last pI:pC injection, 2.0 3 109 plaque-forming
units (PFU) in a total volume of 200 ml (diluted with PBS) were injected
into the tail vein. Blood samples were drawn from the retro-orbital
plexus before and 5 days after virus injection.
Lipid and (Apo)lipoprotein Measurements—From each individual ad-
enovirus-injected mouse, approximately 150 ml of blood was obtained
through retro-orbital bleeding. Total plasma cholesterol and triglycer-
ide levels were measured enzymatically using assay kits from Roche
Molecular Biochemicals and Sigma, respectively.
For determination of the plasma lipoprotein distribution, 60 ml of
pooled plasma was analyzed by fast performance liquid chromatogra-
phy on a Superose 6 column (Sigma), and the cholesterol content of each
fraction was determined spectrofluorometrically as described previ-
ously (10). Pooled plasma before and 5 days after virus infection was
analyzed by immunoblotting with polyclonal antibodies against mouse
apoB, apoE, and apoAI (14, 20). Bound IgG was detected using en-
hanced chemiluminescence (ECL) system (Amersham Pharmacia
Biotech).
Binding of 125I-Labeled RAP to Membranes—Glutathione S-transfer-
ase-RAP was grown and purified as described (21). Approximately 100
mg of RAP was radiolabeled with 125I using the Iodogen method as
described previously (22). Preparation of mouse liver membranes and
membrane binding studies were performed as described (12). Briefly,
livers of individual mice were removed and quickly transferred to 5 ml
of an ice-cold solution of 0.25 M sucrose, 0.1 M Tris, and protease
inhibitors (Roche Molecular Biochemicals), pH 7.4. The livers were
homogenized five times using a tight fitting pestle and then centrifuged
at 500 3 g for 10 min to pellet cell debris. The supernatant was respun
at 10,000 3 g for 15 min. to remove nuclear material. The second
supernatant was centrifuged at 100,000 3 g for 30 min. The resulting
membrane containing pellet was resuspended in 0.5 ml of Tris-buffered
saline in the presence of the protease inhibitor mixture, using a 21
gauge needle. The membrane fraction was stored for up to 1 week in the
dark at 4 °C.
For measurement of 125I-RAP binding, membranes were diluted to a
concentration of 1 mg of protein/ml with incubation buffer (Tris-buff-
ered saline, containing 2 mg/ml albumin and protease inhibitor mix-
ture). Immediately prior to use, this fraction was sonicated (Bioblock
Scientific Vibracell, 30 s, power 2.5, 25% pulse). 100 mg of membranes
was incubated overnight at 4 °C with increasing amounts of 125I-RAP
either in the presence or in the absence of a 100 mg/ml excess of
unlabeled RAP (final incubation volume, 250 ml; n 5 4). Membrane
bound 125I-RAP was separated from unbound RAP by layering a 200-ml
aliquot over 600 ml of 5% (w/v) BSA and centrifuging at 14,000 3 g for
25 min at 4 °C. The supernatant was carefully removed, and the bot-
toms of the vials were cut and counted to measure the amount of
membrane bound 125I-RAP.
Ligand Blotting—Membranes were prepared from mouse livers as
described above, and proteins separated by nondenaturating, nonreduc-
ing SDS gel electrophoresis on 4–15% polyacrylamide gels (50 mg pro-
tein/lane). After separation, the proteins were transferred to nitrocel-
lulose. The nitrocellulose membranes were blocked for 30 min at room
temperature in PBS containing, 0.5% Tween, 2% BSA, and 5% pow-
dered milk, pH 7.4, followed by incubation for 60 min at room temper-
ature with 10 mg/ml peroxidase-conjugated RAP in PBS in blocking
buffer either in absence or presence of an excess of nonconjugated RAP
(100 mg/ml). The nitrocellulose membranes were washed three times
with PBS containing 0.5% Tween and 2% deoxycholic acid with buffer
changes each 5 min. Bound peroxidase-labeled RAP was detected using
the ECL system.
The presence of hepatic LRP was detected using a similar method
and by incubating nitrocellulose membranes with a polyclonal rabbit
antibody against LRP. Bound IgG was detected as described above for
apolipoproteins.
In Vivo Hepatic VLDL-Triglyceride Production—After a 5 h fasting
period, mice were anesthetized by intraperitoneal injection of Nembutal
(80 mg/g body weight). Mice were injected intravenously with Triton
WR1339 (500 mg/kg body weight) using 15% (w/v) Triton solution in
0.9% NaCl (23). At 1, 15, and 30 min after injection, blood samples were
drawn from the tail vein and analyzed for triglycerides as described
above.
Assay of Lipoprotein Lipase and Hepatic Lipase Mass in Mouse
Plasma—Hepatic lipase mass was measured by ELISA developed for
rat HL (24). Mouse LPL was also measured by a sandwich ELISA. A
full-length mouse LPL cDNA kindly provided by Michael Schotz (25)
was subcloned into pQE32 vector for expression in bacteria. The His6
LPL protein was used to generate antibodies in a goat and to construct
a column of mouse LPL Affi-Prep 10 for affinity purification of the
antibodies. The conditions for the assay were the same as those de-
scribed for chicken LPL ELISA (26) with the following exceptions. The
initial incubation of samples with the capture antibodies coated on
microtiter plates was conducted at 4 °C in 0.8 M NaCl, 1% bovine serum
albumin, 0.05% Tween-20, 10 mM sodium phosphate, pH 7.4. The stand-
ard curves ranged from 0.05 to 1.8 ng/well. At 1 ng/well the reading was
0.230 optical density units, and the correlation coefficient was larger
than 0.99. Catalytic activity of LPL and HL in post-heparin plasma
were determined as described below on 20 ml of plasma.
Solid Phase Assay of Interaction of RAP and LPL or HL—To preserve
the integrity of the lipases, all steps were conducted at 4 °C. Microtiter
plates (Corning) were coated with highly purified lipases (27, 28), 10
ng/well of avian LPL or rat HL overnight. Control wells were coated
with nothing or an irrelevant protein (carbonic anhydrase (Sigma)).
After washing three times with PBS/0.05% Tween-20 (Sigma), plates
were blocked overnight with 3% BSA/PBS/0.05% Tween-20. After three
washes, 200-ml aliquots containing 0–500 ng of RAP in 1% BSA/PBS/
0.05% Tween-20 were added to each well in triplicate and incubated
overnight. All subsequent steps were essentially as described by
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Sendak et al. (29). After washing the plate six times, an HRP-conju-
gated rabbit anti-rat-RAP was then added to the wells for 4 h. After six
washes, binding was detected by reaction of HRP with o-phenylenedi-
amine substrate solution. The optical density at 490 nm (OD490) was
measured after a 30-min incubation in the dark.
Effect of RAP on Lipoprotein Lipase and Hepatic Lipase Enzyme
Activity in Vitro—Highly purified LPL (75 ng) purified from chicken
adipose tissue or rat HL (0.034 ng) purified from liver perfusates (27,
28) was preincubated at 4 °C for 30 min in assay tubes with 0, 10, 25,
50, or 100 mg of recombinant glutathione S-transferase-RAP (21). The
reaction was started with the addition of triolein emulsion stabilized
with gum arabic in 400 ml. The reaction mixture in 500 ml contained for
the LPL assay: 1.25 mmol of 13H-labeled triolein with a specific activity
of 500,000 cpm/mmol of fatty acid, 0.02 ml of heat-inactivated rat serum,
2.5 mg of gum arabic, 5 mg of crystalline bovine serum albumin, 0.05
mmol of NaCl, 5 mmol of CaCl2, and 0.1 mmol of Tris-HCl, pH 8.6. For
the HL assay, the reaction mixture was the same with the exceptions
that the rat serum was omitted and the NaCl molarity was increased to
one molar. For both assays, the free fatty acids were extracted by a
liquid/liquid partition system (30) and assayed for radioactivity by
scintillation counting.
The effect of RAP on heparan sulfate proteoglycan-bound lipoprotein
lipase in vitro was performed exactly as described by De Man et al. (31).
The assay was performed using human VLDL-triglycerides as a sub-
strate. VLDL (d , 1.006 lipoproteins) were isolated from human serum
by density gradient ultracentrifugation according to Redgrave et al.
(32).
Plasma Decay of [3H]Trioleate-labeled Neo-chylomicrons in Hepatec-
tomized Mice—[3H]Trioleate neo-chylomicrons (size, 80 nm) were pre-
pared by the sonication and ultracentrifugation procedure exactly as
described by Rensen and van Berkel (33). Mice were anesthetized by
intraperitoneal injection of Nembutal (80 mg/g body weight) and func-
tionally hepatectomized by ligating the hepatic portal vein and the
hepatic artery. Liver was incised to ensure that the liver was excluded
from the circulation. Subsequently, mice were injected via the vena
cava inferior with 100 ml of 500,000 dpm of [3H]trioleate neo-chylomi-
crons either with or without an excess of RAP-glutathione S-transferase
(1 mg/mouse). At indicated time points after injection, 40-ml blood
samples were withdrawn from the vena cava inferior, and the total
radioactivity in 10 ml of serum was estimated.
Statistical Analysis—Data were analyzed using nonparametric
Mann-Whitney rank sum tests. p values less than 0.05 were regarded
as significant.
RESULTS
Plasma Lipid and Lipoprotein Levels after Adenovirus-medi-
ated Gene Transfer of RAP in LDL Receptor and/or LRP-
deficient Mice—We have previously reported the use of the
Cre/loxP recombination system to achieve inducible disruption
of the LRP gene in adult mice. Transgenic mice that were
homozygous for a loxP-flanked (floxed) LRP gene and that
expressed Cre recombinase under the control of the interferon-
inducible MX1 promoter were used to quantitatively inactivate
the LRP gene in the liver of these animals. Inactivation of LRP
in the livers of mice that were also LDL receptor-deficient
resulted in the accumulation of cholesterol-rich remnant li-
poproteins in the circulation. These findings provided unequiv-
ocal in vivo evidence for a physiological role of LRP in the
clearance of cholesterol-rich remnant particles from the circu-
lation, in concert with the LDL receptor.
In the present study we have used mice lacking both LRP
and LDL receptor in their livers to investigate whether another
RAP-sensitive pathway, independent of the LDLR and LRP,
might contribute to the clearance of chylomicron and VLDL
remnant lipoproteins. To this end, we employed adenovirus-
mediated gene transfer to overexpress RAP in mice lacking
both receptors in their livers. Mice that were wild type,
LDLR2/2, LRPflox/flox, MX1cre, or combinations thereof were
analyzed. Animals were injected three times intraperitoneally
with 250 mg of pI:pC at 2-day intervals. One month after the
last pI:pC injection, 2 3 109 PFU of an adenovirus containing
the rat RAP cDNA driven by the cytomegalovirus promoter
(Ad-RAP) were injected into the tail vein of the different mice.
As a control, similar groups of mice were injected with 2 3 109
PFU of an adenovirus encoding the b-galactosidase gene en-
coding driven by the cytomegalovirus promoter (Ad-b-Gal). An-
imals were analyzed within 5 days following virus
administration.
Before adenovirus injection, plasma cholesterol and triglyc-
eride levels were approximately 3-fold higher in
MX1cre1LRPflox/floxLDLR2/2 mice than in LDLR2/2 mice and
in LRPflox/floxLDLR2/2 mice lacking the cre transgene (Table I).
Fast performance liquid chromatography revealed that the in-
crease in total plasma cholesterol was mainly due to an in-
crease in the chylomicron remnant/VLDL and LDL lipoprotein
fractions (Fig. 1A, compare panels d, e, and f). Plasma lipid
levels in MX1cre1LRPflox/flox mice were comparable with those
of LRPflox/flox and wild type control mice, and cholesterol was
contained mainly in the high density lipoprotein fraction (Fig.
1A, panels a–c). Upon Ad-RAP injection, MX1cre1LRPflox/flox-
LDLR2/2 mice showed an increase in total plasma cholesterol
TABLE I
Plasma cholesterol and triglycerides levels after adenovirus-mediated overexpression of receptor-associated protein
Adult LRPflox/flox and LRPflox/floxLDLR2/2 mice either transgenic or nontransgenic for the MX1cre transgene were injected (three times,
intraperitoneally) with 250 mg of pl:pC at 2-day intervals. Similarly, regular wild type and LDLR2/2 mice were treated and included as extra
controls. Four weeks after the last pl:pC injection, the mice were injected intravenously with 2 3 109 PFU of Ad-RAP. As a control similar mice
were injected with 2 3 109 PFU of Ad-bGal. Before and 5 days after adenovirus injection plasma was obtained and analyzed for cholesterol and
triglycerides. Values are represented as the means 6 S.D. (6 range, n 5 2).
Genotype Adenovirus n
Immediately after adenovirus
injection Day 5 after adenovirus injection
Cholesterol Triglycerides Cholesterol Triglycerides
mg/dl mg/dl
MX1cre1LRPflox/flox Ad-b-Gal 3 114 6 15 91 6 5 114 6 18 244 6 99
MX1cre1LRPflox/flox Ad-RAP 6 109 6 30 89 6 15 239 6 132 296 6 117
LRPflox/flox Ad-b-Gal 2 164 6 24 114 6 28 238 6 71 262 6 107
LRPflox/flox Ad-RAP 3 133 6 43 119 6 23 282 6 152 329 6 176
Wild type Ad-b-Gal 2 153 6 1 90 6 6 110 6 33 172 6 13
Wild type Ad-RAP 3 155 6 20 107 6 6 266 6 89 276 6 78
MX1cre1LRPflox/floxLDLR2/2 Ad-b-Gal 3 1113 6 220 516 6 202 1098 6 99 606 6 189
MX1cre1LRPflox/floxLDLR2/2 Ad-RAP 7 927 6 242 350 6 110 1359 6 88a 1350 6 581a
LRPflox/floxLDLR2/2 Ad-b-Gal 2 284 6 23 81 6 9 308 6 57 188 6 61
LRPflox/floxLDLR2/2 Ad-RAP 2 281 6 1 72 6 10 1557 6 116 1054 6 552
LDLR2/2 Ad-b-Gal 3 222 6 34 106 6 5 393 6 117 212 6 58
LDLR2/2 Ad-RAP 3 242 6 44 109 6 25 1585 6 291a 1074 6 279a
a p , 0.05, significantly different from Ad-b-Gal injected mice, using nonparametric Mann-Whitney tests.
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levels of approximately 30%, and total plasma triglyceride lev-
els increased approximately 2-fold as compared with Ad-b-Gal-
injected mice of the same genotype (Table I). Although choles-
terol levels were only slightly elevated, Ad-RAP-injected
MX1cre1LRPflox/floxLDLR2/2 mice showed a dramatic shift in
cholesterol distribution from LDL-sized lipoprotein fractions to
large VLDL-sized lipoproteins, with a concomitant reduction in
high density lipoprotein cholesterol (Fig. 1B, panel f). Total
plasma lipid levels and the lipoprotein profile of Ad-RAP-in-
jected MX1cre1LRPflox/floxLDLR2/2 mice (Fig. 1B, panel f)
closely resembled that of Ad-RAP-injected LRPflox/floxLDLR2/2
or LDLR2/2 mice (Fig. 1B, panels d and e).
Total plasma cholesterol and triglyceride concentrations
were only slightly elevated in Ad-RAP-injected MX1cre1
LRPflox/flox mice compared with Ad-b-Gal-injected mice of the
same genotype (Table I). However, plasma lipid levels in Ad-
RAP-injected MX1cre1LRPflox/flox mice were not different from
Ad-RAP-injected LRPflox/flox or wild type mice. In these mice,
the slight elevation in plasma cholesterol was caused mainly by
the accumulation of large, remnant-sized lipoproteins (Fig. 1B,
panels a–c).
Immunoblot Analysis of Plasma Apoproteins after Adenovi-
rus-mediated RAP Gene Transfer—The effect of RAP overex-
pression on the plasma concentrations of apolipoproteins B100,
B48, E, and AI in the pI:pC-induced wild type, LRPflox/flox,
MX1cre1LRPflox/flox, LDLR2/2, LRPflox/floxLDLR2/2 and
MX1cre1LRPflox/floxLDLR2/2 mice is shown in Fig. 2. Before
adenovirus injections, MX1cre1LRPflox/floxLDLR2/2 mice had
elevated levels of apoB (100148) and apoE as compared with
nontransgenic controls (LRPflox/floxLDLR2/2) and LDLR2/2
mice (Fig. 2A, lanes 4–6). Plasma apolipoprotein levels in
MX1cre1LRPflox/flox mice were comparable with those of
LRPflox/flox and wild type controls (Fig. 2A, lanes 1–3).
Upon Ad-RAP injection, plasma apoB48 and apoE levels
were elevated in MX1cre1LRPflox/floxLDLR2/2 mice (Fig. 2B,
right panel, lane 6) but were not different from apolipoprotein
levels of Ad-b-Gal-injected mice of the same genotype (Fig. 2B,
left panel, lane 6). In addition, plasma apolipoprotein levels in
Ad-RAP-injected MX1cre1LRPflox/floxLDLR2/2 mice were al-
most identical to those of Ad-RAP-injected LRPflox/floxLDLR2/2
and LDLR2/2 mice (Fig. 2B, right panel, lanes 4–6). Consistent
with the decrease in high density lipoprotein cholesterol (Fig.
1b, panels D–F), plasma apoA-I levels were also decreased in
LDLR-deficient mice injected with Ad-RAP (Fig. 2B, right
panel, lanes 4–6).
Ad-RAP-injected MX1cre1LRPflox/flox showed only a slight
elevation in plasma apoB48 and apoE levels as compared with
Ad-b-Gal-injected mice of the same genotype (Fig. 2B, lanes 3,
right and left panels, respectively). Plasma apolipoprotein lev-
els were also not different from Ad-RAP-injected LRPflox/flox or
wild type mice (Fig. 2B, right panel, lanes 1 and 2).
Binding of 125I-Labeled RAP and Peroxidase-labeled RAP to
Liver Membranes—The striking increase in plasma lipids and
shift in lipoprotein profile in Ad-RAP-injected MX1cre1LRPflox/
flox
LDLR2/2 mice indicates that RAP acts on another process
besides the LDL receptor and LRP that is also involved in the
metabolism of triglyceride-rich lipoproteins. To investigate
whether another RAP-binding protein might exist on liver
membranes, we determined the binding of 125I-labeled RAP to
liver membranes from pI:pC-induced adult LRPflox/flox,
MX1cre1LRPflox/flox, LRPflox/floxLDLR2/2, and MX1cre1LRPflox/flox-
LDLR2/2 mice. As shown in Fig. 3, liver membranes from mice
expressing LRP (i.e. LRPflox/flox and LDLR2/2LRPflox/flox; Fig. 3, A
and C) bound RAP with high affinity. In contrast, membranes from
FIG. 1. Distribution of serum cho-
lesterol among lipoprotein fractions
before and 5 days after adenovirus-
mediated RAP gene transfer. Adult
wild type (panel a), LRPflox/flox (panel b),
MX1cre1LRPflox/flox (panel c), LDLR2/2
(panel d), LRPflox/floxLDLR2/2 (panel e),
and MX1cre1LRPflox/floxLDLR2/2 mice
(panel f) were injected (three times, intra-
peritoneally) with 250 mg of pI:pC at
2-day intervals. 4 weeks after the last
pI:pC injection, the mice were injected in-
travenously with 2 3 109 PFU of Ad-RAP
(black circles) or Ad-b-Gal as a control
(open circles). Before (A) and 5 days after
(B) adenovirus injection plasma was ob-
tained from the animals, and lipoproteins
were size-fractionated on a Superose 6
fast performance liquid chromatography
column. Cholesterol content of the indi-
vidual fractions was determined spec-
trofluorometrically. The relative positions
of VLDL, LDL, and high density lipopro-
tein-sized lipoproteins are indicated.
Shown profiles are the average of profiles
obtained from 2–7 individual animals of
the indicated genotype.
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mice lacking LRP (i.e. MX1cre
1
LRPflox/flox and MX1cre1LRPflox/
flox
LDLR2/2; Fig. 3, B and D) did not bind RAP specifically. These
results show that LRP is the only liver membrane protein that
binds RAP with high affinity.
A similar result was obtained when we determined the abil-
ity of RAP to bind to liver membrane proteins by ligand blotting
using peroxidase-labeled RAP (Fig. 4, lower panel). The pres-
ence of LRP was detected by immunoblotting with antibodies
directed against the 85-kDa subunit of LRP (Fig. 4, upper
panel). A prominent band of approximately 515 kDa that bound
RAP was present in the livers of mice expressing LRP and
absent from livers lacking this receptor. No other RAP-binding
protein was detected in these ligand blotting experiments.
These findings further show that LRP is the only high affinity
RAP-binding protein in liver membranes and suggest that the
hyperlipidemia caused by overexpression of RAP in
MX1cre1LRPflox/floxLDLR2/2 is not due to inhibition of an LRP-
independent RAP-binding protein.
Effect of Adenovirus-mediated RAP Gene Transfer on Trig-
lyceride Metabolism—The predominant increase in plasma
triglyceride rather than cholesterol levels in MX1cre1LRPflox/
flox
LDLR2/2 following Ad-RAP-mediated gene transfer suggests
that RAP may directly interfere with triglyceride metabolism.
This effect of RAP overexpression on triglyceride levels may
take place at the level of VLDL-triglyceride production or re-
sult from direct inhibition of triglyceride lipolysis by LPL
and/or HL.
Production of VLDL-triglycerides was measured by deter-
mining the rate of triglyceride secretion in pI:pC-induced
MX1cre1LRPflox/floxLDLR2/2 and wild type control mice 5 days
after injection of 2 3 109 PFU of Ad-RAP or Ad-b-Gal (Fig. 5).
VLDL-triglyceride production rate was similar in all groups of
mice, indicating that RAP overexpression did not affect hepatic
VLDL-triglyceride production.
To determine whether RAP interferes with triglyceride me-
tabolism through a direct effect on LPL and/or HL-mediated
triglyceride hydrolysis, wild type mice were injected with Ad-
FIG. 2. Immunoblot analysis of plasma apoproteins before and
5 days after adenovirus-mediated RAP gene transfer. Adult wild
type (lane 1), LRPflox/flox (lane 2), MX1cre1LRPflox/flox (lane 3), LDLR2/2
(lane 4), LRPflox/floxLDLR2/2 (lane 5), and MX1cre1LRPflox/floxLDLR2/2
mice (lane 6) were injected (three times, intraperitoneally) with 250 mg
of pI:pC at 2-day intervals. 4 weeks after the last pI:pC injection, the
mice were injected intravenously with 2 3 109 PFU of Ad-RAP or
Ad-b-Gal as a control. Before adenovirus injection (A) and 5 days after
injection (B, left and right panel, for Ad-b-Gal and Ad-RAP, respec-
tively) plasma was obtained from the animals. 3 ml of plasma was
separated by SDS gel electrophoresis and immunoblotted with the
indicated polyclonal antibodies against apoB, apoE, and apoAI using
the ECL system. The relative positions of migration of apoB100, B48, E,
and AI are indicated.
FIG. 3. Binding of 125I-labeled RAP to liver membranes. Adult
LRPflox/flox (A), MX1cre1LRPflox/flox (B), LRPflox/floxLDLR2/2 (C), and
MX1cre1LRPflox/floxLDLR2/2 mice (D) were injected (three times, intra-
peritoneally) with 250 mg of pI:pC in 2-day intervals.10 days after the
last injection, membrane fractions were prepared from livers of the
animals. Total (open squares), nonspecific (open circles), and specific
binding (black squares) binding of 125I-labeled RAP to liver membranes
was measured upon incubation of the membranes with indicated
amounts of 125I-labeled RAP overnight at 4 °C as described under
“Experimental Procedures.” Values represent the means 6 S.D. of four
measurements.
FIG. 4. Binding of peroxidase labeled RAP to liver membranes.
Adult wild type (lanes 1 and 2), LRPflox/flox (lanes 3 and 4),
MX1cre1LRPflox/flox (lanes 5 and 6), LDLR2/2 (lanes 7 and 8), LRPflox/
flox
LDLR2/2 (lanes 9 and 10), and MX1cre1LRPflox/floxLDLR2/2 mice
(lanes 11 and 12) were injected (three times, intraperitoneally) with 250
mg of pI:pC at 2-day intervals.10 days after the last injection, membrane
fractions were prepared from livers of the animals, and 50 mg protein/
lane was separated by SDS gel electrophoresis and either used for
ligand blotting (lower panel) with peroxidase labeled RAP (RAP-HRP)
or immunoblotted with an antibody that specifically recognizes the
85-kDa subunit of LRP (RxRaLRP; upper panel). Bound RAP-HRP and
IgG were detected using the ECL system.
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RAP or Ad-b-Gal. Pre- and post-heparin plasma LPL and HL
levels and activities were determined 5 days after adenovirus
injection. As shown in Table II, plasma HL levels and activity
in pre- and post-heparin plasma of Ad-RAP-injected mice were
similar to those of Ad-b-Gal-injected mice. In contrast, LPL
concentrations (protein mass) were increased approximately
7-fold in pre-heparin plasma of Ad-RAP-injected mice as com-
pared with Ad-b-Gal-injected animals. Surprisingly, the accu-
mulating LPL was almost completely enzymatically inactive.
Upon heparin injection, plasma LPL levels increased by the
same amount in animals injected with either virus.
We next determined, in vitro, whether the effect of RAP on
plasma LPL, but not HL, levels and activity may result from a
direct effect of RAP on the activity of these lipases. Although
RAP bound with high affinity to both HL and LPL (Kd 5 8 and
5 nM, respectively; data not shown), it did not affect lipolytic
activity when both were assayed in solution using Triton X-100
stabilized triolein emulsions (Table III). There was also no
effect of RAP on lipolysis when bovine milk LPL was bound to
heparan sulfate proteoglycans, and the substrate employed
was human d,1.006 lipoproteins (Table III). Thus, RAP over-
expression apparently affects the biological activity of LPL in
vivo, although probably not by direct inhibition of enzyme
activity.
To study whether RAP can acutely affect triglyceride hydrol-
ysis by LPL in vivo, we determined plasma triglyceride decay in
functionally hepatectomized mice. As shown in Fig. 6 the
plasma decay of [3H]-trioleate labeled neo-chylomicrons was
not different for hepatectomized mice that were co-injected
with a high dose of RAP (1 mg/mouse) and control-injected
mice. This indicates that the effect of hepatic RAP overexpres-
sion on LPL specific activity in the circulation could not be
mimicked in vivo by intravenous injection of a bolus of RAP and
that the effect of RAP on LPL activity requires a prolonged
overexpression of this protein.
DISCUSSION
In the present study, we demonstrated that a RAP-sensitive
process, independent of the LDL receptor and the LRP, is
involved in the metabolism of triglyceride-rich lipoproteins.
This is illustrated by the fact that adenovirus-mediated over-
expression of RAP increased plasma lipid and lipoprotein levels
in MX1cre1LRPflox/floxLDLR2/2 mice. The presence of this
RAP-sensitive site explains the difference in lipid levels and
lipoprotein profile of LDL receptor-deficient mice in which LRP
was inactivated transiently by RAP overexpression (14) and
animals in which the LRP gene was disrupted by inducible
Cre/loxP-mediated recombination (2).
Our binding and ligand blotting studies with LRP- and LDL-
receptor-deficient mouse liver membranes have shown that the
RAP-mediated effect on the metabolism of triglyceride-rich li-
poproteins was not due to inhibition of an unknown RAP-
sensitive hepatic lipoprotein receptor. Others have postulated
that the uptake of chylomicrons and/or VLDL may also involve
hepatic lipoprotein receptors other than the LDL receptor and
the LRP, for instance a hypothetical lipolysis-stimulated recep-
tor (34) and remnant receptor (35). However, our findings rule
out the possibility of other major RAP-binding proteins in the
liver that may participate in this process.
RAP overexpression strongly affected triglyceride metabo-
lism. This was not due to a RAP-mediated stimulation of he-
patic VLDL-triglyceride production. RAP overexpression re-
sulted in an almost complete inactivation of (postheparin)
plasma LPL. Thus, RAP has a direct or indirect effect on
lipase-mediated conversion of chylomicrons to the smaller rem-
nants, leading to the observed accumulation of large triglycer-
ide-rich particles. This also explains the lack of an effect of RAP
on apolipoprotein levels (Fig. 2B).
RAP binds with high affinity to LPL. Because RAP does not
affect LPL activity in vitro (Table III), we can conclude that
RAP does not bind to the domains essential for the catalytic
activity of the enzyme. Because a high dose of intravenous RAP
protein had no effect on liver-independent triglyceride removal
(Fig. 6), we can also conclude that RAP had no direct effect on
LPL activity within the vascular bed. The heparin-releasable
LPL mass, that is the increment above the pre-heparin level,
was not significantly different in Ad-RAP- or Ad-b-Gal-injected
mice, suggesting that RAP overexpression did not affect the
amount of LPL bound to the endothelium. In addition, RAP
does not compete for binding of apolipoprotein CII with VLDL
or LPL, because no such effect was detectable, in vitro, even at
concentrations of 200–500 mg RAP/ml.
It has been suggested that the VLDL receptor may play a
role in peripheral triglyceride metabolism. The VLDL receptor
and LPL are expressed and localized in peripheral tissues
involved in triglyceride metabolism. Furthermore, the VLDL
receptor binds RAP and LPL with high affinity (36, 37). RAP
may affect the role of the VLDL receptor in LPL-mediated
lipolysis. However, VLDL receptor-deficient mice have a nor-
mal lipoprotein profile (38) and display a normal plasma trig-
lyceride removal rate and normal lipoprotein uptake by periph-
eral tissues (data not shown), suggesting that the RAP-
mediated effect on LPL activity is not related to the VLDL
receptor activity.
RAP gene transfer resulted in greatly elevated levels of in-
active LPL in pre- and post-heparin plasma. The high concen-
tration of inactive LPL in plasma may result from an overpro-
duction of LPL or a defect in its removal. LPL has been shown
to bind LRP both by solid phase assays with purified LRP (39)
and by Western blotting of liver membranes extracts (40). In
addition, in cell culture systems, LRP antibodies have been
shown to inhibit LPL degradation (39). Thus, inactivation of
LRP by RAP is a likely cause for the accumulation of LPL in the
plasma, even in the absence of marked hypertriglyceridemia in
the wild type mice that received Ad-RAP intravenously.
The effect of hepatic RAP overexpression on LPL specific
activity in the circulation could not be mimicked in vitro by
adding RAP to a VLDL lipolysis assay (Table III) or in vivo by
intravenous injection of a bolus of RAP (Fig. 6). This suggests
that RAP may have a function in LPL processing in the capil-
lary bed, possibly by associating with Sortilin (41).
FIG. 5. Production of VLDL-triglycerides after adenovirus-me-
diated RAP gene transfer. Adult wild type (left panel) and
MX1cre1LRPflox/floxLDLR2/2 mice (right panel) were injected (three
times, intraperitoneally) with 250 mg of pI:pC in 2-day intervals. 4
weeks after the last pI:pC injection, the mice were injected intrave-
nously with 2 3 109 PFU of Ad-RAP (black circles) or Ad-b-Gal as a
control (open circles). At 5 days after adenovirus injection, mice were
fasted for 5 h and injected intravenously with Triton WR1339 (500
mg/kg body weight). At 1, 15, and 30 min after injection blood samples
were drawn and analyzed for triglycerides (TG). The increase in serum
triglyceride was normalized to the 1-min point. Values are represented
as the means 6 S.D of six mice.
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The RAP-mediated inhibition of LPL activity resulted in
massive hypertriglyceridemia in mice that lack the LDL recep-
tor or both LDL receptor and LRP. However, wild type mice
and LRP-deficient mice, both having normal LDL receptor ex-
pression, did not display hypertriglyceridemia upon inactiva-
tion of LPL. This is consistent with the observation that mice
lacking both the apoE and LDL receptor genes and not mice
lacking only the apoE gene display massive hypertriglyceri-
demia upon apoE-induced inhibition of lipolysis (42). These
data demonstrate that in contrast to LDL receptor-indepen-
dent pathways, the LDL receptor is capable of removing trig-
lyceride-rich lipoproteins from the circulation, even when the
lipoproteins are poorly lipolyzed.
In summary, our results suggest that RAP affects the con-
version of large triglyceride-rich chylomicrons to smaller rem-
nants by interfering with LPL activation in the periphery and
rule out the contribution of other major RAP-binding proteins
in the liver. This mechanism may play a role in some of the
complex genetic traits that cause hypertriglyceridemic syn-
dromes in man.
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and are expressed as a percentages of the radioactivity present in t 5 1
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